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Increased flux through the glycerolipid synthesis pathway impairs
the ability of insulin to inhibit hepatic gluconeogenesis, but the
exact mechanism remains unknown. To determine the mechanism
by which glycerolipids impair insulin signaling, we overexpressed
glycerol-3-phosphate acyltransferase-1 (GPAT1) in primary mouse
hepatocytes. GPAT1 overexpression impaired insulin-stimulated
phosphorylation of Akt-S473 and -T308, diminished insulin-sup-
pression of glucose production, significantly inhibited mTOR com-
plex 2 (mTORC2) activity and decreased the association of mTOR
and rictor. Conversely, in hepatocytes from Gpat1−/− mice, mTOR-
rictor association and mTORC2 activity were enhanced. However,
this increase in mTORC2 activity in Gpat1−/− hepatocytes was ab-
lated when rictor was knocked down. To determine which lipid
intermediate was responsible for inactivatingmTORC2, we overex-
pressed GPAT1, AGPAT, or lipin to increase the cellular content of
lysophosphatidic acid (LPA), phosphatidic acid (PA), or diacylgly-
cerol (DAG), respectively. The inhibition of mTOR/rictor binding
and mTORC2 activity coincided with the levels of PA and DAG
species that contained 16:0, the preferred substrate of GPAT1. Fur-
thermore, di-16:0-PA strongly inhibited mTORC2 activity and disas-
sociated mTOR/rictor in vitro. Taken together, these data reveal
a signaling pathway by which phosphatidic acid synthesized via
the glycerol-3-phosphate pathway inhibits mTORC2 activity by de-
creasing the association of rictor andmTOR, thereby down-regulat-
ing insulin action. These data demonstrate a critical link between
nutrient excess, TAG synthesis, and hepatic insulin resistance.
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Insulin resistance is frequently associated with triacylglycerol(TAG) accumulation in nonadipose tissues, suggesting that
insulin signaling might be antagonized by a lipid metabolite (1,
2). Glycerol-3-phosphate acyltransferase (GPAT; EC2.3.1.15)
catalyzes the first and committed step in TAG and glycerolipid
synthesis by acylating glycerol-3-phosphate with a long-chain
fatty acyl-CoA to form LPA (3). LPA is further acylated by 1-
acylglycerol-3-phosphate acyltransferase (AGPAT) to form PA,
and then a PA phosphohydrolase (PAP/lipin) hydrolyzes PA to
form DAG, which is esterified by diacylglycerol acyltransferase
(DGAT) to produce TAG.
Each of the four isoforms of GPAT is encoded by a separate
gene and distinguished by subcellular location, substrate pref-
erence, and sensitivity to N-ethylmaleimide (NEM) (3, 4). The
mitochondrial isoform, GPAT1, is of special interest because its
mRNA and activity are up-regulated by SREBP1c when hepatic
lipogenesis and TAG synthesis are enhanced by insulin stimu-
lation (3), and down-regulated by glucagon, fasting, and strep-
tozotocin-induced diabetes (5). GPAT1 activity and mRNA are
highest in tissues that have a high capacity for TAG synthesis,
such as the liver, where GPAT1 contributes 30–50% of the total
GPAT activity. Unlike GPAT-2, -3, and -4, GPAT1 prefers sat-
urated acyl-CoA substrates, particularly palmitate (16:0) (3).
Altering the expression of GPAT1 exemplifies the link be-
tween elevated hepatic TAG content and insulin resistance.
Gpat1−/− mice have markedly lower hepatic content of DAG and
TAG and are protected from hepatic insulin resistance (6). Con-
versely, adenovirus-mediated overexpression of hepatic GPAT1 in
rats increases the intracellular content of DAG and TAG and
induces hepatic and peripheral insulin resistance (7). Although
the mechanisms by which excess glycerolipids contribute to in-
sulin resistance are unclear, each of the three lipid intermediates
produced in the TAG synthetic pathway, LPA, PA, and DAG,
are known signaling molecules. Accordingly, increased DAG
content corresponds with the activation of PKCε, an inhibitor of
insulin signaling (2). Additionally, PA released from membrane
phospholipids by phospholipase D (PLD) may play a role in
regulating another modulator of insulin signaling, the mamma-
lian target of rapamycin (mTOR) (8).
mTOR is a Ser/Thr protein kinase that belongs to the phos-
phoinositide 3-kinase (PI3K)-related kinase family. mTOR is
conserved throughout evolution and functions as a sensor that
regulates cell growth and metabolism in response to nutrient
availability and energy levels (9–11). mTOR exists in two distinct
multiprotein complexes defined by their primary accessory pro-
teins: mTOR complex 1 (mTORC1), which contains raptor
(regulatory associated protein of Tor), and mTOR complex 2
(mTORC2), which contains rictor (rapamycin insensitive com-
panion of T or) (12). mTORC1 activity is regulated by growth
factors, nutrients, and energy levels (13). mTORC1 substrates S6
kinase 1 (S6K1) and eIF4E-binding protein 1 (4E-BP1) regulate
cell growth, but activated S6K1 also provides feedback inhibition
of insulin receptor substrate-1 (IRS1), thereby inhibiting insulin
signaling (14). Although the regulation and substrates of
mTORC2 are only now beginning to be deciphered, mTORC2
phosphorylates and activates Akt at Ser473, enhancing insulin
signaling (15).
Because evidence suggests that exogenous PA and membrane-
derived PA regulate mTORC1 and mTORC2 (15–17), we hy-
pothesized that PA generated by de novo glycerolipid synthesis
may also regulate mTOR signaling. In fact, overexpressing
a microsomal GPAT isoform (GPAT3; LPAAT-theta) in
HEK293T cells increases the phosphorylation of S6K1 (18). We
postulate that lipid intermediates generated by the glycerolipid
synthetic pathway allow mTOR to detect nutrient availability,
not only from amino acids and glucose, but also from lipids.
Nutrient-derived lipid activation of mTOR and subsequent in-
hibition of insulin signaling would provide a critical link between
nutrient excess, TAG synthesis, and insulin resistance. Here, we
present evidence that GPAT1-catalyzed glycerolipid synthesis
produces lipid intermediate species that inhibit mTORC2 ac-
tivity by decreasing the association between mTOR and rictor,
thereby impairing insulin signaling.
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Overexpressing GPAT1 in Hepatocytes Impairs Insulin Signaling. Ab-
lation of Gpat1 in mice results in diminished hepatic TAG con-
tent and protection against diet-induced hepatic insulin resistance
(6), whereas overexpressing Gpat1 increases hepatic TAG con-
tent and induces hepatic insulin resistance (7). To investigate the
mechanisms by which increased glycerolipid synthesis affects
insulin signaling, we overexpressed GPAT1 in primary mouse
hepatocytes. Overexpression was confirmed by Western blotting
(Fig. 1A) and by fourfold increases in total and NEM-resistant
GPAT activity (Fig. 1B). Compared with EGFP-infected hep-
atocytes, GPAT1 overexpression impaired insulin-stimulated
phosphorylation of Akt at both Thr308 and Ser473. Over-
expressing GPAT1 also decreased the phosphorylation of targets
directly downstream of Akt, Ser256-Foxo1 and Ser21-GSK3α,
key enzymes involved in glucose metabolism (Fig. 1 C and D).
Insulin suppresses hepatic gluconeogenesis through Foxo1 tran-
scriptional regulation of phosphoenolpyruvate carboxykinase and
glucose-6-phosphatase (19). In hepatocytes overexpressing GPAT1,
insulin failed to suppress glucose output (Fig. 1E). In confirmation,
GPAT1 overexpression also impaired insulin-stimulated phos-
phorylation of Akt and its downstream targets in 3T3-L1 and HEK
293T cells (Fig. S1). These data demonstrate that GPAT1 over-
expression impairs insulin signaling.
GPAT1-Impaired Insulin Signaling Is Due to Decreased mTORC2
Activity. The effects of GPAT1 on hepatic insulin signaling are
mediated, in part, by DAG activation of PKCε (20), but PA,
which is derived from glycerolipid synthesis, may also regulate
insulin signaling through mTOR. mTORC1 impairs insulin sig-
naling via pS6K1-T389 phosphorylation and subsequent in-
activation of IRS1. The impaired IRS1 signaling results in
decreased insulin signaling through pAkt-T308. Although GPAT1
overexpression decreased pAkt-T308, mTORC1 signaling, char-
acterized by phosphorylation of S6K1-T389 and IRS-S636/639,
was not affected (Fig. S2 A and B). GPAT1 overexpression
slightly reduced the amount of S6K1 protein (P = 0.046), but its
effect on total IRS1 protein was not statistically significant (P =
0.054) (Fig. S2 A and B). Because insulin action is depressed by
enhanced mTORC1/S6K1 signaling (14), the reduced total S6K1
protein is not likely to account for the effect of GPAT1 over-
expression. To understand whether the IRS1/PI3K node mediates
the impairment in insulin signaling caused by GPAT1 over-
expression, we examined IRS1-associated p85 and IRS1 tyrosine
phosphorylation. GPAT1 overexpression did not alter either
IRS1-associated p85 protein amount or tyrosine phosphorylation
of IRS1 (Fig. S2 C and D). However, GPAT1 overexpression
significantly suppressed mTORC2 kinase activity, marked by di-
minished phosphorylation of Akt-S473 (Fig. 2 A and B), and the
reduced mTORC2 activity appeared to be due to decreased
binding of mTOR and rictor (Fig. 2 A and B). GPAT1 over-
expression reduced mLST8-rictor binding in a manner similar to
that of mTOR-rictor, but did not affect Sin1-rictor binding (Fig.
2 A and B), although Sin1 is thought to play an important role in
maintaining mTORC2 assembly (21). These effects were con-
sistent in 3T3-L1 and HEK 293T cells (Fig. S3 A and B). Total
protein levels of mTOR, rictor, Sin1 and mLST8 were not al-
tered (Fig. 2 A and B), indicating that GPAT1 diminished only
the association of mTOR-rictor and/or mLST8-rictor. To further
confirm that mTORC2 mediated the inhibitory effect of GPAT1
overexpression on insulin signaling, we examined phosphor-
NDRG1 (N-myc downstream-regulated gene 1), which occurs
downstream of the mTORC2 target SGK1 and has been used as
a specific readout of mTORC2 signaling (22). GPAT1 over-
expression significantly blocked insulin stimulation of NDRG1
phosphorylation (Fig. 2 C and D), supporting the purported role
of mTORC2.
When purified Flag-GPAT1 protein was added to the in vitro
mTORC2 kinase activity assay, neither Akt phosphorylation nor
mTOR-rictor binding was affected (Fig. S4 A and B), indicating
that the critical feature of GPAT1 is its enzymatic activity. Taken
together, these results suggest that one or more intermediates in
the pathway of glycerolipid synthesis decreases mTOR-rictor
assembly, thereby blocking mTORC2 activity and its downstream
effects on insulin signaling.
Gpat1−/− Hepatocytes Showed Increased mTORC2/Akt Signaling and
Enhanced Association of Rictor and mTOR. In contrast to GPAT1
overexpression, the absence of GPAT1 protects Gpat1−/− mice
against high-fat diet-induced hepatic insulin resistance (6).
Compared with wild-type mice, primary hepatocytes cultured
from high-fat fedGpat1−/− mice had enhanced insulin-stimulated
phosphorylation of Akt-S473, coupled with increased association
of mTOR and rictor and enhanced mTORC2 activity (Fig. 3 A
and B). Knocking down rictor, however, decreased mTOR-rictor
binding and nullified the Gpat1−/−-enhanced insulin signaling
(Fig. 3 C and D). These data again demonstrate that glycer-
olipids generated in the GPAT1-initiated pathway interfere with
the association of mTOR and rictor and that the effects of
GPAT1 on insulin signaling are facilitated through functional
mTORC2 activity.
Impaired mTOR-Rictor Binding and mTORC2 Activity Is Associated
with Increased PA and DAG Species That Contain 16:0. To determine
which lipid intermediate impairs mTORC2 activity and sub-
sequent insulin signaling, we overexpressed GPAT1, AGPAT2,
or PAPase/lipin 2 to manipulate the cellular content of LPA, PA,
and DAG, respectively. Overexpression of these enzymes was
confirmed by Western blotting (Fig. S4C) and by an approxi-
mately sevenfold increase in PAPase activity (Fig. S4D). Al-
though overexpressing lipin 2 had no effect on insulin signaling,
overexpressing either GPAT1 or AGPAT2 suppressed insulin-
stimulated phosphorylation of S473-Akt and diminished mTOR-
rictor binding (Fig. 4 A and B).
Fig. 1. Overexpressing GPAT1 in hepatocytes impairs insulin signaling. Pri-
mary mouse hepatocytes were infected for 24 h to overexpress either EGFP
or Flag-GPAT1. (A) Representative Western blot image of Flag-GPAT1. (B)
Total and NEM-resistant GPAT activity. (C–E) Mouse hepatocytes over-
expressing EGFP or GPAT1 were treated with or without insulin (100 nM) for
10 min. (C) Representative Western blot. (D) Quantitative analysis of data
from C. (E) Glucose output. Asterisk indicates significant differences (P <
0.05) from EGFP total (B) or EGFP basal (D). # indicates significance compared
with EGFP NEM-resistant (B) or EGFP stimulated with insulin (D).
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Because both GPAT1 and AGPAT2 inhibited mTORC2, but
only GPAT1 overexpression increased LPA content (Fig. 5A and
Table S1), mTORC2 signaling was unlikely to have been dis-
rupted by LPA. However, the impaired mTORC2 and insulin
signaling by both GPAT1 and AGPAT2 overexpression was ac-
companied by greater than twofold increases in total cell pal-
mitate (16:0)-containing PA species (Fig. 5B). The increases in
total 16:0-containing PA resulted from individual PA species
increased by GPAT1 or AGPAT2: 16:0–16:0 PA (14.1- and 7.2-
fold, respectively), 16:0–18:0 PA (4.6- and 2.3-fold), 16:0–18:1
PA (1.2- and 2.0-fold), and 16:0–18:2 PA (1.7- and 1.4-fold)
(Table S1). Other PA species did not exhibit this trend (Fig. 5B
and Table S1).
In a similar association, both GPAT1 and AGPAT 2 over-
expression increased the cell content of total and individual
DAG species that contained 16:0, but not other species. GPAT1
and AGPAT2 increased total 16:0-containing DAG by 3.4- and
1.7-fold, respectively, as well as individual species: 16:0–16:0
DAG (17- and 3.1-fold), 16:0–18:1 DAG (2.3- and 1.6-fold), and
16:0–18:2 DAG (7.2- and twofold) (Fig. 5C and Table S1).
Collectively, these results indicate that the synthesis of 16:0-
containing PA and DAG is associated with GPAT1- and
AGPAT2-induced inhibition of rictor-mTOR assembly and
mTORC2 activity. Because, unlike other GPAT isoforms,
GPAT1 has a strong substrate preference for 16:0-CoA, these
PA and DAG species are most likely to be the molecules that
inhibit mTORC2 signaling in this system.
Di-16:0-PA Inhibited Phosphorylation of Akt-S473 and Promoted
mTOR/Rictor Disassembly in Vitro. To provide direct evidence
that lipid species derived from the GPAT pathway interfere with
mTOR/rictor assembly and inhibit mTORC2 activity, we per-
formed an in vitro mTORC2 kinase assay after adding specific
lipids. The two LPA species and the four DAG species tested
showed no effect on mTOR/rictor assembly or on mTORC2
activity (Fig. 6A). In contrast, 16:0–16:0-PA strongly inhibited
both mTOR/rictor assembly and mTORC2 activity in a dose-
dependent manner (Fig. 6 A and B), whereas three other PA
species had no effect (Fig. 6A). Of the LPA, PA, and DAG
species tested, only di-16:0-PA disrupted the association between
rictor and mLST8. These results show that certain PA species
can disassociate a previously formed mTORC2 complex.
PLD1-Derived PA Influences Akt Phosphorylation Through a Mechanism
Other than mTOR/Rictor Assembly. PA hydrolyzed from membrane
phospholipids by PLD exhibits diverse effects on mTOR sig-
naling. Thus, we determined whether PLD1-derived PA inhibi-
ted mTORC2 and insulin signaling. In hepatocytes, serum
activation of PLD-mediated phosphorylation of Akt-S473 was
similar to insulin (Fig. 7). However, inhibiting PLD with 1-bu-
tanol abolished the insulin-stimulating effect of serum. Although
PLD1-derived PA affects Akt signaling, neither activating nor
inhibiting PLD1 altered mTOR-rictor assembly. This result
suggests that, unlike GPAT1- and AGPAT2-derived PA, PA
derived from PLD1 influences Akt phosphorylation through
a mechanism other than mTOR/rictor assembly.
Discussion
The major finding of this study is that overexpressing GPAT1
generates lipid intermediates that decrease mTORC2 activity
and impair insulin signaling (Fig. S5). Our previous data dem-
onstrated that overexpressing GPAT1 in rats induces insulin
resistance (7), and conversely, that the absence of Gpat1 protects
mice from high-fat-diet-induced hepatic insulin resistance (6). In
both studies, the changes in insulin sensitivity probably occurred
because of the altered flux through the pathway of glycerolipid
synthesis initiated by GPAT. Although hepatic TAG content is
strongly associated with insulin resistance, TAG is a neutral lipid
sequestered in lipid droplets and is unlikely to inhibit insulin
action. On the other hand, synthesis of the lipid intermediates
LPA, PA, and DAG is tightly regulated and maintained at low
levels because these molecules are critical intermediates for de
Fig. 2. GPAT1-impaired insulin signaling is due to decreased mTORC2 activity. Primary mouse hepatocytes infected to overexpress either EGFP or Flag-GPAT1
were treated with or without insulin (100 nM) for 10 min. (A) Representative images of Western blots of rictor-IP or cell lysates. (B) Quantitative analysis of
data from A. (C) Representative images of Western blots of cell lysates. (D) Quantitative analysis of data from C. Data in A and B represent results from five
independent experiments performed in triplicate. Asterisk indicates significant differences (P < 0.05) from EGFP basal; #, significantly different from EGFP
stimulated with insulin; GβL, mLST8.











novo synthesized glycerolipids as well as bioactive signaling mol-
ecules. Although the levels of lipid intermediates change tran-
siently during normal physiological responses, increases in their
steady-state content are likely to result in metabolic dysfunction.
GPAT1-mediated changes in insulin signaling have been at-
tributed to DAG activation of novel isoforms of PKC (2) which
phosphorylate serine residues of IRS1 and impair insulin sig-
naling. In muscle and liver, fatty acid-induced insulin resistance
is partially mediated through DAG activation of PKCθ (23) and
PKCε (24), and decreasing the hepatic content of DAG reduces
PKCε activation and protects rats against dietary fat-induced
insulin resistance (25). Because in GPAT1-overexpressing rats,
an increase in hepatic DAG corresponded with increased acti-
vation of PKCε, whereas in Gpat1−/− mice both hepatic DAG
and activated PKCε were low (6, 7), we concluded that DAG
activation of PKC mediates insulin resistance. In the current
Fig. 3. Gpat1−/− hepatocytes have increased
mTORC2/Akt signaling and enhanced association of
rictor and mTOR. Hepatocytes were isolated from
WT or Gpat1−/− mice fed a high-fat diet for three
weeks. Isolated hepatocytes were treated with or
without insulin (100 nM) for 10 min. (A) Represen-
tative images of Western blots from cell lysates and
rictor-IP product. (B) Quantitative analysis of data
from A. Asterisk indicates significant difference
compared with EGFP basal; #, significant difference
compared with EGFP stimulated with insulin. Mouse
primary hepatocytes of WT or Gpat1−/− mice fed
a high-fat diet were infected with LacZ-shRNA or
rictor-shRNA adenovirus for 72 h and treated with
or without insulin (100 nM) for 10 min. (C) Repre-
sentative images of Western blots from cell lysates.
(D) Quantitative analysis of data from C. Asterisk
indicates significant differences (P < 0.05) from EGFP
basal; #, significantly different from EGFP stimulated
with insulin. Different letters represent significant
differences within basal or insulin treatment.
Fig. 4. Overexpressing GPAT1 or AGPAT2, but not Lipin2, in mouse hep-
atocytes impairs mTOR/rictor association and insulin signaling. Primary
hepatocytes overexpressing GPAT1, AGPAT2, or Lipin2, were treated with or
without insulin (100 nM) for 10 min. (A) Representative images of Western
blots from cell lysates and rictor-IP product. (B) Quantitative analysis of data
from A. Asterisk indicates significant differences (P < 0.05) from EGFP basal;
#, significantly different from EGFP stimulated with insulin.
Fig. 5. Overexpressing GPAT1 and AGPAT2 in mouse hepatocytes increased
the levels of PA and DAG species that contained 16:0. Lipids were quantified
from primary hepatocytes overexpressing GPAT1, AGPAT2, or Lipin2. (A)
LPA. (B) PA. (C) DAG content. Asterisk indicates significant differences
(P < 0.05) from EGFP.
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study, elevated DAG induced by overexpressing GPAT1 or
AGPAT2 paralleled the inhibition of mTORC2 activity, thus
supporting a possible second role for DAG-mediated insulin
resistance via inactivation of mTORC2 signaling. Despite these
strong associations, much of the DAG produced via de novo
glycerolipid synthesis, as opposed to membrane hydrolysis, is
likely to be sequestered in lipid droplets (26), in theory, ren-
dering the DAG less available for signaling functions; PKCε
activation would require DAG to escape these lipid droplets.
Unlike DAG, water-soluble LPA and PA, which are generated
by de novo glycerolipid synthesis, are not confined to lipid
droplets. LPA interferes with insulin signaling through PKC-
dependent phosphorylation and inactivation of GSK3 (27). In
our model, however, LPA is an improbable signal for glycer-
olipid-mTORC2 signaling because of the disconnect between
LPA content and impaired mTORC2 activity. However, PA
content was strongly associated with the dissociation of mTOR
and rictor and the decrease in mTORC2 activity. Both exoge-
nous PA and the PA derived from PLD membrane hydrolysis
activate mTORC1 and mTORC2, each of which has distinct
effects on insulin signaling. mTORC1 provides feedback in-
hibition of insulin signaling through p70S6K phosphorylation
and inactivation of IRS1 (14), whereas mTORC2 phosphorylates
S473-Akt and augments insulin signaling (15). A critical role for
mTORC2 in insulin signaling is evident in both muscle-specific
(MRic−/−) and adipose-specific (FRic−/−) rictor knockout mice.
Defective glucose transport and insulin signaling in muscle from
MRic−/− mice cause mild glucose intolerance (28). Likewise,
FRic−/− mice have impaired glucose transport in adipocytes,
resulting in hepatic and whole-body insulin resistance (29).
PA derived from PLD-mediated hydrolysis of membrane
phospholipids directly activates mTORC1 by interacting with the
FKBP12-rapamycin-binding (FRB) domain of mTOR and sta-
bilizing mTORC1 (8, 17, 30, 31). In fact, PA is critical for
mTORC1 activation by nutrients like glucose and amino acids
(32). Similarly, suppressing PLD-derived PA inhibits the asso-
ciation of mTOR and rictor and leads to diminished mTORC2
activity (15, 33). Our data suggesting that PA produced via the
glycerolipid synthesis pathway decreases mTOR/rictor associa-
tion and mTORC2 activity creates an interesting paradox that
could be resolved if PA derived from glycerolipid synthesis were
functionally different from PA derived from membrane hydro-
lysis. How can the same molecule, albeit derived from different
sources, engender opposite effects on mTORC2 signaling? Pre-
sumably, PA from both pools would interact with the same FRB
domain of mTOR. To mediate opposing effects on function, one
might invoke differences in PA structure. In support of this hy-
pothesis, our data show that only PA species that contained 16:0
were associated with the inhibition of mTORC2 activity and only
16:0–16:0-PA directly caused dissociation of the mTOR/rictor
complex. The PA species predominant in PLD-derived PA ac-
tivation of mTORC1 and -2 are not known. However, the mo-
lecular species of PA released by PLD vary, probably depending
on the agent used to stimulate PLD and the cell type used (34–
38). In no case, however, did species containing 16:0 pre-
dominate. Characterizing the nature of the hepatic pools of PA
derived from PLD and from de novo synthesis will be needed
to understand normal and dysfunctional nutrient lipid signaling,
particularly as it relates to nutrient oversupply and insulin
resistance.
Although we found that only 16:0–16:0-PA inhibited mTORC2
activity in vitro, it is possible that other PA and DAG species may
be able to inhibit mTORC2 activity in living cells. Our experi-
ment required disassociation of the mTORC2 complex after it
had already formed; it may be easier for an inhibitory lipid to
prevent the initial association than to disrupt an existing complex.
The relatively high concentration of 16:0–16:0-PA that was re-
quired for inhibition may also reflect this difficulty in promoting
Fig. 6. Di-16:0-PA inhibits the phosphorylation of Akt at S473 and promotes mTOR/rictor disassembly in vitro. Lipid vesicles were added to the rictor-IP beads
and then mTORC2 kinase was assayed. (A) Representative images of Western blots from rictor-IP and kinase assay product. (B) Representative images of
Western blots from rictor-IP product and quantitative analysis. Lipid vesicles of each species were added at 150 uM. Asterisk indicates P < 0.05 compared with
the control incubated with buffer alone; GβL, mLST8.
Fig. 7. PLD1-derived PA influences Akt phosphorylation through a mecha-
nism other than mTOR/rictor assembly. Primary mouse hepatocytes were
serum-starved for 24 h and then stimulated with serum (30%) or insulin (100
nM) and with or without 1-butanol (0.5%) for 30 min. (A) Representative
images of Western blots from cell lysate and rictor-IP products. (B) Quanti-
tative analysis of data from A. Asterisk indicates significant differences (P <
0.05) compared with serum starvation (starved); #, significantly different
compared with serum stimulation.











complex dissociation. However, even in vivo, the concentration
of 16:0–16:0-PA is unlikely to be uniform within the cell, and
because we added PA in vesicles, we cannot know its concen-
tration at the surface of the mTORC2 complex. Similarly, be-
cause of the difficulty in solubilizing long-chain DAGs and
presenting them effectively to a protein complex, we cannot rule
out the possibility that, in vivo, DAG might also exert an effect
on mTORC2.
Our findings demonstrate that mTOR is a molecular sensor
for multiple types of nutrients, including glucose, amino acids,
and now lipids. The data reveal a signaling pathway in which lipid
intermediates synthesized via the glycerolipid synthetic pathway
inhibit mTORC2 activity by dissociating rictor and mTOR, thus
impairing insulin action. Our data also suggest that the PA mo-
lecular species derived from PLD hydrolysis and de novo glyc-
erolipid synthesis comprise functionally distinct lipid pools that
have opposing effects on mTOR signaling. Taken together, this
study demonstrates that 16:0-containing PA is strongly associated
with the inhibition of mTORC2 activity and downstream insulin
signaling and that PA provides a critical link between excess
nutrient intake, hepatic TAG synthesis, and insulin resistance.
Materials and Methods
GPAT Activity. Hepatocytes were homogenized in 10 mM Tris (pH 7.4), 250 mM
sucrose, 1 mMDTT, 1.0 mM EDTA. Membranes were isolated by centrifuging at
100,000 × g for 1 h. Protein was measured by the bicinchoninic acid method
with BSA as the standard. GPAT specific activity was assayed for 10 min at 25 °C
with 800 μM [3H]glycerol-3-phosphate and 100 μM palmitoyl-CoA in the
presence or absence of 2 mM N-ethylmaleimide (NEM), which inhibits the
isoforms GPAT-2, 3 and 4.
Antibody reagents animal care, cell culture methods, enzyme activity and
glucose output assays, recombinant adenoviruses, cell lipid measurements
and analyses, immunoprecipitations and kinase activity assays, and statistical
analyses are detailed in SI Materials and Methods.
ACKNOWLEDGMENTS. We thank Dr. Anil Kumar (University of Virginia) for
generating the mouse rictor-shRNA adenovirus and Dr. Liza Makowski for
helpful advice. This study was supported by National Institutes of Health
Grants DK56598 (to R.A.C.), DK083157 (to A.A.W.), AR048914 (to J.C.), and
DK28312 (to T.E.H.).
1. Li LO, Klett EL, Coleman RA (2010) Acyl-CoA synthesis, lipid metabolism and lip-
otoxicity. Biochim Biophys Acta 1801:246–251.
2. Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: Un-
ravelling the mechanism. Lancet 375:2267–2277.
3. Coleman RA, Lee DP (2004) Enzymes of triacylglycerol synthesis and their regulation.
Prog Lipid Res 43:134–176.
4. Coleman RA (2007) How do I fatten thee? Let me count the ways.... Cell Metab 5:
87–89.
5. Shin D-H, Paulauskis JD, Moustaïd N, Sul HS (1991) Transcriptional regulation of p90
with sequence homology to Escherichia coli glycerol-3-phosphate acyltransferase.
J Biol Chem 266:23834–23839.
6. Neschen S, et al. (2005) Prevention of hepatic steatosis and hepatic insulin resistance
in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice.
Cell Metab 2:55–65.
7. Nagle CA, et al. (2007) Hepatic overexpression of glycerol-sn-3-phosphate acyl-
transferase 1 in rats causes insulin resistance. J Biol Chem 282:14807–14815.
8. Sun Y, Chen J (2008) mTOR signaling: PLD takes center stage. Cell Cycle 7:3118–3123.
9. Sabers CJ, et al. (1995) Isolation of a protein target of the FKBP12-rapamycin complex
in mammalian cells. J Biol Chem 270:815–822.
10. Brown EJ, et al. (1994) A mammalian protein targeted by G1-arresting rapamycin-
receptor complex. Nature 369:756–758.
11. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994) RAFT1: A
mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is
homologous to yeast TORs. Cell 78:35–43.
12. Loewith R, et al. (2002) Two TOR complexes, only one of which is rapamycin sensitive,
have distinct roles in cell growth control. Mol Cell 10:457–468.
13. Kimura N, et al. (2003) A possible linkage between AMP-activated protein kinase
(AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells
8:65–79.
14. Zhang J, Gao Z, Yin J, Quon MJ, Ye J (2008) S6K directly phosphorylates IRS-1 on Ser-
270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2.
J Biol Chem 283:35375–35382.
15. Toschi A, et al. (2009) Regulation of mTORC1 and mTORC2 complex assembly by
phosphatidic acid: Competition with rapamycin. Mol Cell Biol 29:1411–1420.
16. Fang Y, et al. (2003) PLD1 regulates mTOR signaling and mediates Cdc42 activation of
S6K1. Curr Biol 13:2037–2044.
17. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J (2001) Phosphatidic acid-
mediated mitogenic activation of mTOR signaling. Science 294:1942–1945.
18. Tang W, et al. (2006) Identification of a novel human lysophosphatidic acid acyl-
transferase, LPAAT-theta, which activates mTOR pathway. J Biochem Mol Biol 39:
626–635.
19. Cheng Z, White MF (2011) Targeting Forkhead box O1 from the concept to metabolic
diseases: lessons from mouse models. Antioxid Redox Signal 14:649–661.
20. Jornayvaz FR, et al. (2011) Hepatic insulin resistance in mice with hepatic over-
expression of diacylglycerol acyltransferase 2. Proc Natl Acad Sci USA 108:5748–5752.
21. Frias MA, et al. (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its iso-
forms define three distinct mTORC2s. Curr Biol 16:1865–1870.
22. García-Martínez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydro-
phobic motif phosphorylation and activation of serum- and glucocorticoid-induced
protein kinase 1 (SGK1). Biochem J 416:375–385.
23. Kim JK, et al. (2004) PKC-theta knockout mice are protected from fat-induced insulin
resistance. J Clin Invest 114:823–827.
24. De Fea K, Roth RA (1997) Protein kinase C modulation of insulin receptor substrate-1
tyrosine phosphorylation requires serine 612. Biochemistry 36:12939–12947.
25. Choi CS, et al. (2007) Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not
DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and
insulin resistance. J Biol Chem 282:22678–22688.
26. Kumashiro N, et al. (2011) Cellular mechanism of insulin resistance in nonalcoholic
fatty liver disease. Proc Natl Acad Sci USA 108:16381–16385.
27. Fang X, et al. (2002) Convergence of multiple signaling cascades at glycogen synthase
kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophospha-
tidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol
22:2099–2110.
28. Kumar A, et al. (2008) Muscle-specific deletion of rictor impairs insulin-stimulated
glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol 28:
61–70.
29. Kumar A, et al. (2010) Fat cell-specific ablation of rictor in mice impairs insulin-reg-
ulated fat cell and whole-body glucose and lipid metabolism. Diabetes 59:1397–1406.
30. Sun Y, et al. (2008) Phospholipase D1 is an effector of Rheb in the mTOR pathway.
Proc Natl Acad Sci USA 105:8286–8291.
31. Hornberger TA, et al. (2006) The role of phospholipase D and phosphatidic acid in the
mechanical activation of mTOR signaling in skeletal muscle. Proc Natl Acad Sci USA
103:4741–4746.
32. Xu L, et al. (2011) Phospholipase D mediates nutrient input to mTORC1. J Biol Chem
286:25477–25486.
33. Toschi A, Lee E, Gadir N, Ohh M, Foster DA (2008) Differential dependence of hyp-
oxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 283:
34495–34499.
34. Beckman BS, Mallia C, Clejan S (1996) Molecular species of phospholipids in a murine
stem-cell line responsive to erythropoietin. Biochem J 314:861–867.
35. Lee C, Fisher SK, Agranoff BW, Hajra AK (1991) Quantitative analysis of molecular
species of diacylglycerol and phosphatidate formed upon muscarinic receptor acti-
vation of human SK-N-SH neuroblastoma cells. J Biol Chem 266:22837–22846.
36. Pettitt TR, et al. (1997) Diacylglycerol and phosphatidate generated by phospholi-
pases C and D, respectively, have distinct fatty acid compositions and functions.
Phospholipase D-derived diacylglycerol does not activate protein kinase C in porcine
aortic endothelial cells. J Biol Chem 272:17354–17359.
37. Divecha N, Lander DJ, Scott TW, Irvine RF (1991) Molecular species analysis of 1,2-
diacylglycerols and phosphatidic acid formed during bombesin stimulation of Swiss
3T3 cells. Biochim Biophys Acta 1093:184–188.
38. El Bawab S, et al. (1997) Selective stimulation of a cAMP-specific phosphodiesterase
(PDE4A5) isoform by phosphatidic acid molecular species endogenously formed in rat
thymocytes. Eur J Biochem 247:1151–1157.
1672 | www.pnas.org/cgi/doi/10.1073/pnas.1110730109 Zhang et al.
